Cargando…

High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs

BACKGROUND: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ES...

Descripción completa

Detalles Bibliográficos
Autores principales: Romo-Ibáñez, Álvaro, Calatrava-Hernández, Elisabeth, Gutiérrez-Soto, Blanca, Pérez-Ruiz, Mercedes, Navarro-Marí, José María, Gutiérrez-Fernández, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290529/
https://www.ncbi.nlm.nih.gov/pubmed/32566630
http://dx.doi.org/10.21037/atm.2020.02.158
_version_ 1783545698051948544
author Romo-Ibáñez, Álvaro
Calatrava-Hernández, Elisabeth
Gutiérrez-Soto, Blanca
Pérez-Ruiz, Mercedes
Navarro-Marí, José María
Gutiérrez-Fernández, José
author_facet Romo-Ibáñez, Álvaro
Calatrava-Hernández, Elisabeth
Gutiérrez-Soto, Blanca
Pérez-Ruiz, Mercedes
Navarro-Marí, José María
Gutiérrez-Fernández, José
author_sort Romo-Ibáñez, Álvaro
collection PubMed
description BACKGROUND: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ESBL). The objective of this study was to evaluate the potential of this medium to detect other types of resistant bacteria. METHODS: Vancomycin, cefoxitin, imipenem, and cefepime disks were used to measure growth on CHROMID ESBL medium of β-lactam-resistant Gram-negative (83 with ESBL, 57 with carbapenemases, 35 with AmpC and 3 Stenotrophomonas maltophilia) and Gram-positive [37 vancomycin-susceptible (vancoS) microorganisms and 21 vancomycin-resistant (vancoR) Enterococcus faecium] clinical isolates (retrospective study) and colonization by the aforementioned bacteria (prospective study), using 649 rectal swabs, 314 pharyngeal swabs, and 44 swabs from other localizations. RESULTS: Retrospective study: species grown on the medium exhibited different colors. Growth on the medium was observed for: all ESBL enterobacteria, which were susceptible to imipenem and cefoxitin; 95% of isolates with carbapenemases, mostly resistant to imipenem; 80% of those with AmpC; 86% of vancoR E. faecium isolates; and 42% of vancoS E. faecalis isolates, with large growth inhibition halos around the vancomycin disk. Prospective study: vancoR E. faecium, ESBL Klebsiella, Pseudomonas with carbapenemases, A. baumannii (mostly from rectal swabs), S. maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia (mostly from pharyngeal swabs) were isolated from the 246 positive samples. CONCLUSIONS: CHROMID ESBL medium permitted the differential growth of Gram-negative bacteria, many with ESBL and carbapenemases. ESBL enterobacteria were susceptible to imipenem, carbapenemase-producing microorganisms grew around the imipenem disk, and vancoR E. faecium was isolated on the medium. Results of the prospective study demonstrate the potential clinical relevance of this medium. S. maltophilia was more frequently detected with pharyngeal swabs and ESBL Klebsiella, A. baumannii, and Pseudomonas with rectal swabs.
format Online
Article
Text
id pubmed-7290529
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-72905292020-06-19 High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs Romo-Ibáñez, Álvaro Calatrava-Hernández, Elisabeth Gutiérrez-Soto, Blanca Pérez-Ruiz, Mercedes Navarro-Marí, José María Gutiérrez-Fernández, José Ann Transl Med Original Article on Advances in Laboratory Tests for Infectious Diseases BACKGROUND: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ESBL). The objective of this study was to evaluate the potential of this medium to detect other types of resistant bacteria. METHODS: Vancomycin, cefoxitin, imipenem, and cefepime disks were used to measure growth on CHROMID ESBL medium of β-lactam-resistant Gram-negative (83 with ESBL, 57 with carbapenemases, 35 with AmpC and 3 Stenotrophomonas maltophilia) and Gram-positive [37 vancomycin-susceptible (vancoS) microorganisms and 21 vancomycin-resistant (vancoR) Enterococcus faecium] clinical isolates (retrospective study) and colonization by the aforementioned bacteria (prospective study), using 649 rectal swabs, 314 pharyngeal swabs, and 44 swabs from other localizations. RESULTS: Retrospective study: species grown on the medium exhibited different colors. Growth on the medium was observed for: all ESBL enterobacteria, which were susceptible to imipenem and cefoxitin; 95% of isolates with carbapenemases, mostly resistant to imipenem; 80% of those with AmpC; 86% of vancoR E. faecium isolates; and 42% of vancoS E. faecalis isolates, with large growth inhibition halos around the vancomycin disk. Prospective study: vancoR E. faecium, ESBL Klebsiella, Pseudomonas with carbapenemases, A. baumannii (mostly from rectal swabs), S. maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia (mostly from pharyngeal swabs) were isolated from the 246 positive samples. CONCLUSIONS: CHROMID ESBL medium permitted the differential growth of Gram-negative bacteria, many with ESBL and carbapenemases. ESBL enterobacteria were susceptible to imipenem, carbapenemase-producing microorganisms grew around the imipenem disk, and vancoR E. faecium was isolated on the medium. Results of the prospective study demonstrate the potential clinical relevance of this medium. S. maltophilia was more frequently detected with pharyngeal swabs and ESBL Klebsiella, A. baumannii, and Pseudomonas with rectal swabs. AME Publishing Company 2020-05 /pmc/articles/PMC7290529/ /pubmed/32566630 http://dx.doi.org/10.21037/atm.2020.02.158 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article on Advances in Laboratory Tests for Infectious Diseases
Romo-Ibáñez, Álvaro
Calatrava-Hernández, Elisabeth
Gutiérrez-Soto, Blanca
Pérez-Ruiz, Mercedes
Navarro-Marí, José María
Gutiérrez-Fernández, José
High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs
title High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs
title_full High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs
title_fullStr High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs
title_full_unstemmed High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs
title_short High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs
title_sort high clinical impact of rapid susceptibility testing on chromid esbl(®) medium directly from swabs
topic Original Article on Advances in Laboratory Tests for Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290529/
https://www.ncbi.nlm.nih.gov/pubmed/32566630
http://dx.doi.org/10.21037/atm.2020.02.158
work_keys_str_mv AT romoibanezalvaro highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs
AT calatravahernandezelisabeth highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs
AT gutierrezsotoblanca highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs
AT perezruizmercedes highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs
AT navarromarijosemaria highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs
AT gutierrezfernandezjose highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs